{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:16:18Z","timestamp":1786979778099,"version":"build-2736575974"},"reference-count":86,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,1,26]],"date-time":"2021-01-26T00:00:00Z","timestamp":1611619200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,1,26]],"date-time":"2021-01-26T00:00:00Z","timestamp":1611619200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Synthetic cannabinoids (SCs) are the largest class of novel psychoactive substances (NPS) and are associated with an increased risk of overdosing and adverse events such as psychosis. JWH-018 is one of the earliest SCs and still widely available in large parts of the world. Controlled studies to assess the safety and behavioural profiles of SCs are extremely scarce.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>The current study was designed to assess the psychotomimetic effects of a moderate dose of JWH-018.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Twenty-four healthy participants (10 males, 14 females) entered a placebo-controlled, double blind, within-subjects trial and inhaled vapour of placebo or 75\u03bcg\/kg bodyweight JWH-018. To ascertain a minimum level of intoxication, a booster dose of JWH-018 was administered on an as-needed basis. The average dose of JWH-018 administered was 5.52 mg. Subjective high, dissociative states (CADSS), psychedelic symptoms (Bowdle), mood (POMS) and cannabis reinforcement (SCRQ) were assessed within a 4.5-h time window after drug administration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>JWH-018 caused psychedelic effects, such as altered internal and external perception, and dissociative effects, such as amnesia, derealisation and depersonalisation and induced feelings of confusion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Overall, these findings suggest that a moderate dose of JWH-018 induces pronounced psychotomimetic symptoms in healthy participants with no history of mental illness, which confirms that SCs pose a serious risk for public health.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00213-021-05768-0","type":"journal-article","created":{"date-parts":[[2021,1,26]],"date-time":"2021-01-26T18:02:40Z","timestamp":1611684160000},"page":"1251-1261","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Psychotomimetic symptoms after a moderate dose of a synthetic cannabinoid (JWH-018): implications for psychosis"],"prefix":"10.1007","volume":"239","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6071-1758","authenticated-orcid":false,"given":"Eef L.","family":"Theunissen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes T.","family":"Reckweg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia R. P. W.","family":"Hutten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim P. C.","family":"Kuypers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan W.","family":"Toennes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merja A.","family":"Neukamm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Halter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes G.","family":"Ramaekers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,26]]},"reference":[{"key":"5768_CR1","doi-asserted-by":"publisher","unstructured":"Adamowicz P (2020) Blood concentrations of synthetic cannabinoids. Clin Toxicol (Phila):1-6. https:\/\/doi.org\/10.1080\/15563650.2020.1787429","DOI":"10.1080\/15563650.2020.1787429"},{"issue":"3","key":"5768_CR2","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJMoa1610300","volume":"376","author":"AJ Adams","year":"2017","unstructured":"Adams AJ, Banister SD, Irizarry L, Trecki J, Schwartz M, Gerona R (2017) \u201cZombie\u201d outbreak caused by the synthetic cannabinoid AMB-FUBINACA in New York. N Engl J Med 376(3):235\u2013242. https:\/\/doi.org\/10.1056\/NEJMoa1610300","journal-title":"N Engl J Med"},{"issue":"3","key":"5768_CR3","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/dta.2752","volume":"12","author":"RM Alam","year":"2020","unstructured":"Alam RM, Keating JJ (2020) Adding more \u201cSpice\u201d to the pot; a review of the chemistry and pharmacology of newly emerging heterocyclic synthetic cannabinoid receptor agonists. Drug Testing and Analysis 12(3):297\u2013315. https:\/\/doi.org\/10.1002\/dta.2752","journal-title":"Drug Testing and Analysis"},{"issue":"2","key":"5768_CR4","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/s0306-4522(98)00675-7","volume":"91","author":"R Alonso","year":"1999","unstructured":"Alonso R, Voutsinos B, Fournier M, Labie C, Steinberg R, Souilhac J, Le Fur G, Soubrie P (1999) Blockade of cannabinoid receptors by SR141716 selectively increases Fos expression in rat mesocorticolimbic areas via reduced dopamine D2 function. Neuroscience 91(2):607\u2013620. https:\/\/doi.org\/10.1016\/s0306-4522(98)00675-7","journal-title":"Neuroscience"},{"key":"5768_CR5","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association (2013) Diagnostic and Statistical Manual of Mental Disorders: DSM, 5th edn. American Psychiatric Publishing, Arlington, VA","DOI":"10.1176\/appi.books.9780890425596"},{"issue":"2","key":"5768_CR6","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.biopsych.2008.01.003","volume":"64","author":"NC Andreasen","year":"2008","unstructured":"Andreasen NC, Pierson R (2008) The role of the cerebellum in schizophrenia. Biol Psychiatry 64(2):81\u201388. https:\/\/doi.org\/10.1016\/j.biopsych.2008.01.003","journal-title":"Biol Psychiatry"},{"key":"5768_CR7","doi-asserted-by":"publisher","unstructured":"Aung MM, Griffin G, Huffman JW, Wu MJ, Keel C, Yang B, Showalter VM, Abood ME, Martin BR (2000) Influence of the N-1 alkyl chain length of cannabimimetic indoles upon CB1 and CB2 receptor binding. Drug Alcohol Depend 60 (2):133-140. Doi. https:\/\/doi.org\/10.1016\/S0376-8716(99)00152-0","DOI":"10.1016\/S0376-8716(99)00152-0"},{"issue":"10","key":"5768_CR8","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1038\/sj.npp.1301344","volume":"32","author":"M Ballmaier","year":"2007","unstructured":"Ballmaier M, Bortolato M, Rizzetti C, Zoli M, Gessa G, Heinz A, Spano P (2007) Cannabinoid receptor antagonists counteract sensorimotor gating deficits in the phencyclidine model of psychosis. Neuropsychopharmacology 32(10):2098\u20132107. https:\/\/doi.org\/10.1038\/sj.npp.1301344","journal-title":"Neuropsychopharmacology"},{"issue":"10","key":"5768_CR9","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1111\/j.1360-0443.2012.03928.x","volume":"107","author":"W Bosker","year":"2012","unstructured":"Bosker W, Kuypers K, Theunissen E, Surinx A, Blankespoor R, Skopp G, Jeffery W, Walls H, Van Leeuwen C, Ramaekers J (2012) Medicinal THC (dronabinol) impairs on-the-road driving performance of occasional and heavy cannabis users but is not detected in Standardized Field Sobriety Tests. Addiction 107(10):1837\u20131844","journal-title":"Addiction"},{"issue":"1","key":"5768_CR10","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1097\/00000542-199801000-00015","volume":"88","author":"AT Bowdle","year":"1998","unstructured":"Bowdle AT, Radant AD, Cowley DS, Kharasch ED, Strassman RJ, Roy-Byrne PP (1998) Psychedelic effects of ketamine in healthy volunteers: relationship to steady-state plasma concentrations. Anesthesiology 88(1):82\u201388. https:\/\/doi.org\/10.1097\/00000542-199801000-00015","journal-title":"Anesthesiology"},{"issue":"1","key":"5768_CR11","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1023\/A:1024465317902","volume":"11","author":"JD Bremner","year":"1998","unstructured":"Bremner JD, Krystal JH, Putnam FW, Southwick SM, Marmar C, Charney DS, Mazure CM (1998) Measurement of dissociative states with the clinician-administered dissociative states scale (CADSS). J Trauma Stress 11(1):125\u2013136. https:\/\/doi.org\/10.1023\/A:1024465317902","journal-title":"J Trauma Stress"},{"key":"5768_CR12","doi-asserted-by":"publisher","unstructured":"Buchsbaum MS (1990) The frontal lobes, basal ganglia, and temporal lobes as sites for schizophrenia. Schizophr Bull 16 (3):379-389. DOI. https:\/\/doi.org\/10.1093\/schbul\/16.3.379","DOI":"10.1093\/schbul\/16.3.379"},{"key":"5768_CR13","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.drugalcdep.2014.08.005","volume":"144","author":"MS Castaneto","year":"2014","unstructured":"Castaneto MS, Gorelick DA, Desrosiers NA, Hartman RL, Pirard S, Huestis MA (2014) Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications. Drug Alcohol Depend 144:12\u201341. https:\/\/doi.org\/10.1016\/j.drugalcdep.2014.08.005","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"5768_CR14","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s00213-002-1169-0","volume":"164","author":"HV Curran","year":"2002","unstructured":"Curran HV, Brignell C, Fletcher S, Middleton P, Henry J (2002) Cognitive and subjective dose-response effects of acute oral Delta 9-tetrahydrocannabinol (THC) in infrequent cannabis users. Psychopharmacology (Berl) 164(1):61\u201370. https:\/\/doi.org\/10.1007\/s00213-002-1169-0","journal-title":"Psychopharmacology (Berl)"},{"issue":"5","key":"5768_CR15","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1080\/15563650.2019.1647344","volume":"58","author":"S Darke","year":"2020","unstructured":"Darke S, Duflou J, Farrell M, Peacock A, Lappin J (2020) Characteristics and circumstances of synthetic cannabinoid-related death. Clin Toxicol 58(5):368\u2013374. https:\/\/doi.org\/10.1080\/15563650.2019.1647344","journal-title":"Clin Toxicol"},{"issue":"9","key":"5768_CR16","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1016\/j.clinthera.2018.08.002","volume":"40","author":"MA De Luca","year":"2018","unstructured":"De Luca MA, Fattore L (2018) Therapeutic use of synthetic cannabinoids: still an open issue? Clin Ther 40(9):1457\u20131466","journal-title":"Clin Ther"},{"issue":"5","key":"5768_CR17","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S0893-133X(02)00343-3","volume":"27","author":"H de Wit","year":"2002","unstructured":"de Wit H, Enggasser JL, Richards JB (2002) Acute administration of d-amphetamine decreases impulsivity in healthy volunteers. Neuropsychopharmacology 27(5):813\u2013825. https:\/\/doi.org\/10.1016\/S0893-133X(02)00343-3","journal-title":"Neuropsychopharmacology"},{"key":"5768_CR18","doi-asserted-by":"publisher","first-page":"616","DOI":"10.3389\/fnins.2019.00616","volume":"13","author":"B Derntl","year":"2019","unstructured":"Derntl B, Hornung J, Sen ZD, Colic L, Li M, Walter M (2019) Interaction of sex and age on the dissociative effects of ketamine action in young healthy participants. Front Neurosci 13:616. https:\/\/doi.org\/10.3389\/fnins.2019.00616","journal-title":"Front Neurosci"},{"issue":"6","key":"5768_CR19","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1192\/bjp.bp.109.064220","volume":"195","author":"M Di Forti","year":"2009","unstructured":"Di Forti M, Morgan C, Dazzan P, Pariante C, Mondelli V, Marques TR, Handley R, Luzi S, Russo M, Paparelli A (2009) High-potency cannabis and the risk of psychosis. The British Journal of Psychiatry 195(6):488\u2013491. https:\/\/doi.org\/10.1192\/bjp.bp.109.064220","journal-title":"The British Journal of Psychiatry"},{"issue":"3","key":"5768_CR20","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/s2215-0366(14)00117-5","volume":"2","author":"M Di Forti","year":"2015","unstructured":"Di Forti M, Marconi A, Carra E, Fraietta S, Trotta A, Bonomo M, Bianconi F, Gardner-Sood P, O'Connor J, Russo M, Stilo SA, Marques TR, Mondelli V, Dazzan P, Pariante C, David AS, Gaughran F, Atakan Z, Iyegbe C, Powell J, Morgan C, Lynskey M, Murray RM (2015) Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study. Lancet Psychiatry 2(3):233\u2013238. https:\/\/doi.org\/10.1016\/s2215-0366(14)00117-5","journal-title":"Lancet Psychiatry"},{"issue":"8","key":"5768_CR21","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1038\/sj.npp.1300496","volume":"29","author":"DC D'Souza","year":"2004","unstructured":"D'Souza DC, Perry E, MacDougall L, Ammerman Y, Cooper T, Braley G, Gueorguieva R, Krystal JH (2004) The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology 29(8):1558\u20131572. https:\/\/doi.org\/10.1038\/sj.npp.1300496","journal-title":"Neuropsychopharmacology"},{"key":"5768_CR22","unstructured":"European Monitoring Centre for Drugs and Drug Addiction (2017) Perspectives on drugs: synthetic cannabinoids in Europe. Update June 2017. Publications Office of the European Union. https:\/\/www.emcdda.europa.eu\/system\/files\/publications\/2753\/POD_Synthetic%20cannabinoids_0.pdf. Accessed 4 November 2019"},{"key":"5768_CR23","unstructured":"European Monitoring Centre for Drugs and Drug Addiction (2019) EU Drug Markets Report 2019. Accessed 13 January 2019"},{"issue":"10","key":"5768_CR24","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1111\/j.1360-0443.2010.03119.x","volume":"105","author":"S Every-Palmer","year":"2010","unstructured":"Every-Palmer S (2010) Warning: legal synthetic cannabinoid-receptor agonists such as JWH-018 may precipitate psychosis in vulnerable individuals. Addiction 105(10):1859\u20131860","journal-title":"Addiction"},{"issue":"2-3","key":"5768_CR25","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.drugalcdep.2011.01.012","volume":"117","author":"S Every-Palmer","year":"2011","unstructured":"Every-Palmer S (2011) Synthetic cannabinoid JWH-018 and psychosis: an explorative study. Drug Alcohol Depend 117(2-3):152\u2013157. https:\/\/doi.org\/10.1016\/j.drugalcdep.2011.01.012","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"5768_CR26","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.lfs.2013.09.017","volume":"97","author":"WE Fantegrossi","year":"2014","unstructured":"Fantegrossi WE, Moran JH, Radominska-Pandya A, Prather PL (2014) Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to \u0394(9)-THC: mechanism underlying greater toxicity? Life Sci 97(1):45\u201354. https:\/\/doi.org\/10.1016\/j.lfs.2013.09.017","journal-title":"Life Sci"},{"issue":"7","key":"5768_CR27","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.biopsych.2016.02.001","volume":"79","author":"L Fattore","year":"2016","unstructured":"Fattore L (2016) Synthetic cannabinoids\u2014further evidence supporting the relationship between cannabinoids and psychosis. Biol Psychiatry 79(7):539\u2013548. https:\/\/doi.org\/10.1016\/j.biopsych.2016.02.001","journal-title":"Biol Psychiatry"},{"issue":"9","key":"5768_CR28","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.biopsych.2008.05.032","volume":"64","author":"A Fornito","year":"2008","unstructured":"Fornito A, Yung AR, Wood SJ, Phillips LJ, Nelson B, Cotton S, Velakoulis D, McGorry PD, Pantelis C, Y\u00fccel M (2008) Anatomic abnormalities of the anterior cingulate cortex before psychosis onset: an MRI study of ultra-high-risk individuals. Biol Psychiatry 64(9):758\u2013765","journal-title":"Biol Psychiatry"},{"issue":"10","key":"5768_CR29","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1177\/0960327111421945","volume":"31","author":"MB Forrester","year":"2012","unstructured":"Forrester MB, Kleinschmidt K, Schwarz E, Young A (2012) Synthetic cannabinoid and marijuana exposures reported to poison centers. Hum Exp Toxicol 31(10):1006\u20131011. https:\/\/doi.org\/10.1177\/0960327111421945","journal-title":"Hum Exp Toxicol"},{"key":"5768_CR30","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.neuro.2018.11.004","volume":"70","author":"MB Gatch","year":"2019","unstructured":"Gatch MB, Forster MJ (2019) Cannabinoid-like effects of five novel carboxamide synthetic cannabinoids. Neurotoxicology 70:72\u201379. https:\/\/doi.org\/10.1016\/j.neuro.2018.11.004","journal-title":"Neurotoxicology"},{"issue":"6","key":"5768_CR31","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1001\/archpsyc.56.6.537","volume":"56","author":"JM Goldstein","year":"1999","unstructured":"Goldstein JM, Goodman JM, Seidman LJ, Kennedy DN, Makris N, Lee H, Tourville J, Caviness VS Jr, Faraone SV, Tsuang MT (1999) Cortical abnormalities in schizophrenia identified by structural magnetic resonance imaging. Arch Gen Psychiatry 56(6):537\u2013547. https:\/\/doi.org\/10.1001\/archpsyc.56.6.537","journal-title":"Arch Gen Psychiatry"},{"issue":"1","key":"5768_CR32","first-page":"53","volume":"26","author":"SM Gurney","year":"2014","unstructured":"Gurney SM, Scott K, Kacinko S, Presley B, Logan B (2014) Pharmacology, toxicology, and adverse effects of synthetic cannabinoid drugs. Forensic Sci Rev 26(1):53\u201378","journal-title":"Forensic Sci Rev"},{"key":"5768_CR33","doi-asserted-by":"publisher","unstructured":"Hall W, Degenhardt L (2009) Adverse health effects of non-medical cannabis use. The Lancet 374 (9698):1383-1391. https:\/\/doi.org\/10.1016\/S0140-6736(09)61037-0","DOI":"10.1016\/S0140-6736(09)61037-0"},{"issue":"9140","key":"5768_CR34","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1016\/S0140-6736(98)05021-1","volume":"352","author":"W Hall","year":"1998","unstructured":"Hall W, Solowij N (1998) Adverse effects of cannabis. Lancet 352(9140):1611\u20131616. https:\/\/doi.org\/10.1016\/S0140-6736(98)05021-1","journal-title":"Lancet"},{"issue":"1","key":"5768_CR35","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.pnpbp.2010.11.002","volume":"35","author":"JE Hallak","year":"2011","unstructured":"Hallak JE, Dursun SM, Bosi DC, de Macedo LRH, Machado-de-Sousa JP, Abr\u00e3o J, Crippa JA, McGuire P, Krystal JH, Baker GB (2011) The interplay of cannabinoid and NMDA glutamate receptor systems in humans: preliminary evidence of interactive effects of cannabidiol and ketamine in healthy human subjects. Prog Neuropsychopharmacol Biol Psychiatry 35(1):198\u2013202. https:\/\/doi.org\/10.1016\/j.pnpbp.2010.11.002","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"7","key":"5768_CR36","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1002\/dta.1839","volume":"8","author":"RL Hartman","year":"2016","unstructured":"Hartman RL, Brown TL, Milavetz G, Spurgin A, Gorelick DA, Gaffney G, Huestis MA (2016) Controlled vaporized cannabis, with and without alcohol: subjective effects and oral fluid-blood cannabinoid relationships. Drug testing and analysis 8(7):690\u2013701. https:\/\/doi.org\/10.1002\/dta.1839","journal-title":"Drug testing and analysis"},{"issue":"7","key":"5768_CR37","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1046\/j.1360-0443.2001.967102312.x","volume":"96","author":"SJ Heishman","year":"2001","unstructured":"Heishman SJ, Singleton EG, Liguori A (2001) Marijuana Craving Questionnaire: development and initial validation of a self-report instrument. Addiction 96(7):1023\u20131034. https:\/\/doi.org\/10.1046\/j.1360-0443.2001.967102312.x","journal-title":"Addiction"},{"issue":"3","key":"5768_CR38","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1093\/schbul\/sbi027","volume":"31","author":"C Henquet","year":"2005","unstructured":"Henquet C, Murray R, Linszen D, van Os J (2005) The environment and schizophrenia: the role of cannabis use. Schizophr Bull 31(3):608\u2013612. https:\/\/doi.org\/10.1093\/schbul\/sbi027","journal-title":"Schizophr Bull"},{"issue":"5","key":"5768_CR39","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1073\/pnas.87.5.1932","volume":"87","author":"M Herkenham","year":"1990","unstructured":"Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, De Costa BR, Rice KC (1990) Cannabinoid receptor localization in brain. Proceedings of the national Academy of sciences 87(5):1932\u20131936. https:\/\/doi.org\/10.1073\/pnas.87.5.1932","journal-title":"Proceedings of the national Academy of sciences"},{"issue":"9-10","key":"5768_CR40","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1002\/dta.1483","volume":"5","author":"M Hermanns-Clausen","year":"2013","unstructured":"Hermanns-Clausen M, Kneisel S, Hutter M, Szabo B, Auw\u00e4rter V (2013a) Acute intoxication by synthetic cannabinoids\u2013four case reports. Drug Test Anal 5(9-10):790\u2013794. https:\/\/doi.org\/10.1002\/dta.1483","journal-title":"Drug Test Anal"},{"issue":"3","key":"5768_CR41","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1111\/j.1360-0443.2012.04078.x","volume":"108","author":"M Hermanns-Clausen","year":"2013","unstructured":"Hermanns-Clausen M, Kneisel S, Szabo B, Auw\u00e4rter V (2013b) Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings. Addiction 108(3):534\u2013544","journal-title":"Addiction"},{"issue":"6","key":"5768_CR42","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1080\/15563650.2017.1393082","volume":"56","author":"M Hermanns-Clausen","year":"2018","unstructured":"Hermanns-Clausen M, M\u00fcller D, Kithinji J, Angerer V, Franz F, Eyer F, Neurath H, Liebetrau G, Auw\u00e4rter V (2018) Acute side effects after consumption of the new synthetic cannabinoids AB-CHMINACA and MDMB-CHMICA. Clin Toxicol 56(6):404\u2013411. https:\/\/doi.org\/10.1080\/15563650.2017.1393082","journal-title":"Clin Toxicol"},{"issue":"2","key":"5768_CR43","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1124\/jpet.117.240572","volume":"362","author":"L Hruba","year":"2017","unstructured":"Hruba L, McMahon LR (2017) Apparent affinity estimates and reversal of the effects of synthetic cannabinoids AM-2201, CP-47,497, JWH-122, and JWH-250 by rimonabant in rhesus monkeys. J Pharmacol Exp Ther 362(2):278\u2013286. https:\/\/doi.org\/10.1124\/jpet.117.240572","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"5768_CR44","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s00127-004-0701-4","volume":"39","author":"EC Hunter","year":"2004","unstructured":"Hunter EC, Sierra M, David AS (2004) The epidemiology of depersonalisation and derealisation. Soc Psychiatry Psychiatr Epidemiol 39(1):9\u201318. https:\/\/doi.org\/10.1007\/s00127-004-0701-4","journal-title":"Soc Psychiatry Psychiatr Epidemiol"},{"issue":"1-3","key":"5768_CR45","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.schres.2015.01.033","volume":"162","author":"TA Iseger","year":"2015","unstructured":"Iseger TA, Bossong MG (2015) A systematic review of the antipsychotic properties of cannabidiol in humans. Schizophr Res 162(1-3):153\u2013161. https:\/\/doi.org\/10.1016\/j.schres.2015.01.033","journal-title":"Schizophr Res"},{"issue":"2","key":"5768_CR46","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1192\/bjp.178.2.116","volume":"178","author":"A Johns","year":"2001","unstructured":"Johns A (2001) Psychiatric effects of cannabis. The British Journal of Psychiatry 178(2):116\u2013122. https:\/\/doi.org\/10.1192\/bjp.178.2.116","journal-title":"The British Journal of Psychiatry"},{"issue":"1","key":"5768_CR47","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1097\/JCP.0b013e318204825b","volume":"31","author":"DL Kelly","year":"2011","unstructured":"Kelly DL, Gorelick DA, Conley RR, Boggs DL, Linthicum J, Liu F, Feldman S, Ball MP, Wehring HJ, McMahon RP (2011) Effects of the cannabinoid-1 receptor antagonist rimonabant on psychiatric symptoms in overweight people with schizophrenia: a randomized, double-blind, pilot study. J Clin Psychopharmacol 31(1):86\u201391. https:\/\/doi.org\/10.1097\/JCP.0b013e318204825b","journal-title":"J Clin Psychopharmacol"},{"issue":"2-3","key":"5768_CR48","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1054\/plef.2001.0351","volume":"66","author":"A Lichtman","year":"2002","unstructured":"Lichtman A, Varvel S, Martin B (2002) Endocannabinoids in cognition and dependence. Prostaglandins Leukot Essent Fatty Acids 66(2-3):269\u2013285. https:\/\/doi.org\/10.1054\/plef.2001.0351","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"issue":"5","key":"5768_CR49","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1093\/schbul\/sbaa037","volume":"46","author":"E Longden","year":"2020","unstructured":"Longden E, Branitsky A, Moskowitz A, Berry K, Bucci S, Varese F (2020) The relationship between dissociation and symptoms of psychosis: a meta-analysis. Schizophr Bull 46(5):1104\u20131113. https:\/\/doi.org\/10.1093\/schbul\/sbaa037","journal-title":"Schizophr Bull"},{"issue":"2","key":"5768_CR50","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.pbb.2005.02.017","volume":"81","author":"T Lundqvist","year":"2005","unstructured":"Lundqvist T (2005) Cognitive consequences of cannabis use: comparison with abuse of stimulants and heroin with regard to attention, memory and executive functions. Pharmacology, biochemistry, and behavior 81(2):319\u2013330. https:\/\/doi.org\/10.1016\/j.pbb.2005.02.017","journal-title":"Pharmacology, biochemistry, and behavior"},{"key":"5768_CR51","doi-asserted-by":"crossref","unstructured":"Mackie K (2005) Distribution of cannabinoid receptors in the central and peripheral nervous system. In: Cannabinoids. Springer, pp 299-325","DOI":"10.1007\/3-540-26573-2_10"},{"issue":"6","key":"5768_CR52","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1176\/appi.ajp.161.6.975","volume":"161","author":"HY Meltzer","year":"2004","unstructured":"Meltzer HY, Arvanitis L, Bauer D, Rein W, Group M-TS (2004) Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. Am J Psychiatry 161(6):975\u2013984. https:\/\/doi.org\/10.1176\/appi.ajp.161.6.975","journal-title":"Am J Psychiatry"},{"issue":"1","key":"5768_CR53","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1159\/000506635","volume":"3","author":"G Meredith","year":"2020","unstructured":"Meredith G, DeLollis M, Shad MU (2020) Potential treatment for overdose with synthetic cannabinoids. Medical Cannabis and Cannabinoids 3(1):25\u201326","journal-title":"Medical Cannabis and Cannabinoids"},{"issue":"3","key":"5768_CR54","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1055\/s-0042-103425","volume":"84","author":"S M\u00f6rkl","year":"2016","unstructured":"M\u00f6rkl S, Blesl C, Wurm WE, Tmava A (2016) Acute psychosis after consumption of synthetic cannabinoids. Fortschr Neurol Psychiatr 84(3):150\u2013154. https:\/\/doi.org\/10.1055\/s-0042-103425","journal-title":"Fortschr Neurol Psychiatr"},{"issue":"1","key":"5768_CR55","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.schres.2009.12.001","volume":"118","author":"H M\u00fcller","year":"2010","unstructured":"M\u00fcller H, Sperling W, K\u00f6hrmann M, Huttner HB, Kornhuber J, Maler J-M (2010) The synthetic cannabinoid Spice as a trigger for an acute exacerbation of cannabis induced recurrent psychotic episodes. Schizophr Res 118(1):309\u2013310","journal-title":"Schizophr Res"},{"issue":"19","key":"5768_CR56","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1002\/rcm.6354","volume":"26","author":"RA Musah","year":"2012","unstructured":"Musah RA, Domin MA, Cody RB, Lesiak AD, John Dane A, Shepard JR (2012) Direct analysis in real time mass spectrometry with collision-induced dissociation for structural analysis of synthetic cannabinoids. Rapid Commun Mass Spectrom 26(19):2335\u20132342. https:\/\/doi.org\/10.1002\/rcm.6354","journal-title":"Rapid Commun Mass Spectrom"},{"key":"5768_CR57","doi-asserted-by":"publisher","unstructured":"Oberenko AV, Kachin SV, Sagalakov S\u0410 (2019) Types of synthetic cannabinoids seized from illicit trafficking in the territory of the Siberian Federal District (Russia) between 2009\u20132018. Forensic Sci Int 302:109902. ARTN 109902 https:\/\/doi.org\/10.1016\/j.forsciint.2019.109902","DOI":"10.1016\/j.forsciint.2019.109902"},{"issue":"4","key":"5768_CR58","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1002\/hup.2312","volume":"28","author":"D Papanti","year":"2013","unstructured":"Papanti D, Schifano F, Botteon G, Bertossi F, Mannix J, Vidoni D, Impagnatiello M, Pascolo-Fabrici E, Bonavigo T (2013) \u201cSpiceophrenia\u201d: a systematic overview of \u201cspice\u201d-related psychopathological issues and a case report. Human Psychopharmacology: Clinical and Experimental 28(4):379\u2013389. https:\/\/doi.org\/10.1002\/hup.2312","journal-title":"Human Psychopharmacology: Clinical and Experimental"},{"issue":"3","key":"5768_CR59","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1111\/j.1521-0391.2012.00222.x","volume":"21","author":"S Peglow","year":"2012","unstructured":"Peglow S, Buchner J, Briscoe G (2012) Synthetic cannabinoid induced psychosis in a previously nonpsychotic patient. The American journal on addictions 21(3):287\u2013288. https:\/\/doi.org\/10.1111\/j.1521-0391.2012.00222.x","journal-title":"The American journal on addictions"},{"key":"5768_CR60","doi-asserted-by":"publisher","unstructured":"Radhakrishnan R, Wilkinson ST, D\u2019Souza DC (2014) Gone to pot\u2013a review of the association between cannabis and psychosis. Front Psychiatry 5:54. ARTN 54. https:\/\/doi.org\/10.3389\/fpsyt.2014.00054","DOI":"10.3389\/fpsyt.2014.00054"},{"issue":"10","key":"5768_CR61","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.1038\/sj.npp.1301068","volume":"31","author":"JG Ramaekers","year":"2006","unstructured":"Ramaekers JG, Kauert G, van Ruitenbeek P, Theunissen EL, Schneider E, Moeller MR (2006) High-potency marijuana impairs executive function and inhibitory motor control. Neuropsychopharmacology 31(10):2296\u20132303. https:\/\/doi.org\/10.1038\/sj.npp.1301068","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"5768_CR62","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s00213-006-0508-y","volume":"188","author":"M Ranganathan","year":"2006","unstructured":"Ranganathan M, D'Souza DC (2006) The acute effects of cannabinoids on memory in humans: a review. Psychopharmacology (Berl) 188(4):425\u2013444. https:\/\/doi.org\/10.1007\/s00213-006-0508-y","journal-title":"Psychopharmacology (Berl)"},{"issue":"2-2","key":"5768_CR63","doi-asserted-by":"publisher","first-page":"208","DOI":"10.3109\/15622970801908047","volume":"11","author":"P Roser","year":"2010","unstructured":"Roser P, Vollenweider FX, Kawohl W (2010) Potential antipsychotic properties of central cannabinoid (CB1) receptor antagonists. The World Journal of Biological Psychiatry 11(2-2):208\u2013219. https:\/\/doi.org\/10.3109\/15622970801908047","journal-title":"The World Journal of Biological Psychiatry"},{"issue":"1","key":"5768_CR64","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.euroneuro.2013.11.002","volume":"24","author":"C Schubart","year":"2014","unstructured":"Schubart C, Sommer I, Fusar-Poli P, De Witte L, Kahn R, Boks M (2014) Cannabidiol as a potential treatment for psychosis. Eur Neuropsychopharmacol 24(1):51\u201364. https:\/\/doi.org\/10.1016\/j.euroneuro.2013.11.002","journal-title":"Eur Neuropsychopharmacol"},{"issue":"2","key":"5768_CR65","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.pnpbp.2012.04.017","volume":"39","author":"KA Seely","year":"2012","unstructured":"Seely KA, Lapoint J, Moran JH, Fattore L (2012) Spice drugs are more than harmless herbal blends: a review of the pharmacology and toxicology of synthetic cannabinoids. Prog Neuropsychopharmacol Biol Psychiatry 39(2):234\u2013243. https:\/\/doi.org\/10.1016\/j.pnpbp.2012.04.017","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"1","key":"5768_CR66","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s00406-019-00978-2","volume":"269","author":"N Solowij","year":"2019","unstructured":"Solowij N, Broyd S, L-m G, van Hell H, Martelozzo D, Rueb K, Todd J, Liu Z, Galettis P, Martin J (2019) A randomised controlled trial of vaporised \u0394 9-tetrahydrocannabinol and cannabidiol alone and in combination in frequent and infrequent cannabis users: acute intoxication effects. Eur Arch Psychiatry Clin Neurosci 269(1):17\u201335","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"5768_CR67","unstructured":"Steup C (n.d.) Untersuchung des Handelsproduktes 'Spice'. THC Pharm GmbH. http:\/\/usualredant.de\/downloads\/analyse-thc-pharm-spice-jwh-018.pdf. Accessed 1 May 2016"},{"issue":"2","key":"5768_CR68","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s40429-014-0014-y","volume":"1","author":"S Tai","year":"2014","unstructured":"Tai S, Fantegrossi WE (2014) Synthetic cannabinoids: pharmacology, behavioral effects, and abuse potential. Curr Addict Rep 1(2):129\u2013136. https:\/\/doi.org\/10.1007\/s40429-014-0014-y","journal-title":"Curr Addict Rep"},{"issue":"1","key":"5768_CR69","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/15563650.2015.1110590","volume":"54","author":"RJ Tait","year":"2016","unstructured":"Tait RJ, Caldicott D, Mountain D, Hill SL, Lenton S (2016) A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment. Clin Toxicol 54(1):1\u201313. https:\/\/doi.org\/10.3109\/15563650.2015.1110590","journal-title":"Clin Toxicol"},{"key":"5768_CR70","doi-asserted-by":"crossref","unstructured":"Theunissen EL, Kauert GF, Toennes SW, Moeller MR, Sambeth A, Blanchard MM, Ramaekers JG (2012) Neurophysiological functioning of occasional and heavy cannabis users during THC intoxication. Psychopharmacology (Berl) 220 (2):341-350. 10.1007\/s00213-011-2479-x","DOI":"10.1007\/s00213-011-2479-x"},{"issue":"1","key":"5768_CR71","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/bph.14066","volume":"175","author":"EL Theunissen","year":"2018","unstructured":"Theunissen EL, Hutten NR, Mason NL, Toennes SW, Kuypers KP, Sousa Fernandes Perna EB, Ramaekers JG (2018) Neurocognition and subjective experience following acute doses of the synthetic cannabinoid JWH-018: a phase 1, placebo-controlled, pilot study. Br J Pharmacol 175(1):18\u201328. https:\/\/doi.org\/10.1111\/bph.14066","journal-title":"Br J Pharmacol"},{"issue":"1","key":"5768_CR72","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1089\/can.2018.0047","volume":"4","author":"EL Theunissen","year":"2019","unstructured":"Theunissen EL, Hutten NR, Mason NL, Toennes SW, Kuypers KP, Ramaekers JG (2019) Neurocognition and subjective experience following acute doses of the synthetic cannabinoid JWH-018: responders versus non-responders. Cannabis and Cannabinoid Research 4(1):51\u201361","journal-title":"Cannabis and Cannabinoid Research"},{"key":"5768_CR73","doi-asserted-by":"publisher","unstructured":"Theunissen EL, Reckweg JT, Hutten NRPW, Kuypers KP, Toennes SW, Neukamm MA, Halter S, Ramaekers JG (2021) Intoxication by a synthetic cannabinoid (JWH-018) causes cognitive and psychomotor impairment in recreational cannabis users.\u00a0Pharmacology, Biochemistry and Behavior. https:\/\/doi.org\/10.1016\/j.pbb.2021.173118","DOI":"10.1016\/j.pbb.2021.173118"},{"key":"5768_CR74","unstructured":"United Nations office on Drugs and Crime (2013) The challenge of new psychoactive substances. A report from the Global SMART Programme. United Nations Office on Drugs and Crime. https:\/\/www.unodc.org\/documents\/scientific\/NPS_Report.pdf. Accessed 1 March 2017"},{"key":"5768_CR75","unstructured":"United Nations Office on Drugs and Crime (UNODC) (2020) Current NPS Threats. Volume II. vol 2020. UNODC Laboratory and Scientific Section, Vienna"},{"key":"5768_CR76","unstructured":"United Nations Publications (2019) World Drug Report 2019. Booklet 5 cannabis and hallucinogens. https:\/\/wdr.unodc.org\/wdr2019\/prelaunch\/WDR19_Booklet_5_CANNABIS_HALLUCINOGENS.pdf. Accessed 15 January 2020"},{"issue":"703","key":"5768_CR77","doi-asserted-by":"publisher","first-page":"703","DOI":"10.3389\/fnins.2018.00703","volume":"12","author":"L Uttl","year":"2018","unstructured":"Uttl L, Szczurowska E, H\u00e1jkov\u00e1 K, Horsley RR, \u0160tefkov\u00e1 K, Hlo\u017eek T, \u0160\u00edchov\u00e1 K, Bal\u00edkov\u00e1 M, Kucha\u0159 M, Micale V, P\u00e1len\u00ed\u010dek T (2018) Behavioral and pharmacokinetic profile of indole-derived synthetic cannabinoids JWH-073 and JWH-210 as compared to the phytocannabinoid \u03949-THC in rats. Front Neurosci 12(703):703. https:\/\/doi.org\/10.3389\/fnins.2018.00703","journal-title":"Front Neurosci"},{"issue":"3","key":"5768_CR78","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.psychres.2015.04.028","volume":"228","author":"D van Heugten-Van der Kloet","year":"2015","unstructured":"van Heugten-Van der Kloet D, Giesbrecht T, van Wel J, Bosker WM, Kuypers KP, Theunissen EL, Spronk DB, Verkes RJ, Merckelbach H, Ramaekers JG (2015) MDMA, cannabis, and cocaine produce acute dissociative symptoms. Psychiatry Res 228(3):907\u2013912. https:\/\/doi.org\/10.1016\/j.psychres.2015.04.028","journal-title":"Psychiatry Res"},{"issue":"3","key":"5768_CR79","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1177\/0269881114563633","volume":"29","author":"J Van Wel","year":"2015","unstructured":"Van Wel J, Spronk D, Kuypers K, Theunissen E, Toennes S, Verkes R, Ramaekers JG (2015) Psychedelic symptoms of cannabis and cocaine use as a function of trait impulsivity. Journal of psychopharmacology 29(3):324\u2013334","journal-title":"Journal of psychopharmacology"},{"issue":"1","key":"5768_CR80","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.drugalcdep.2011.07.011","volume":"120","author":"R Vandrey","year":"2012","unstructured":"Vandrey R, Dunn KE, Fry JA, Girling ER (2012) A survey study to characterize use of spice products (synthetic cannabinoids). Drug Alcohol Depend 120(1):238\u2013241. https:\/\/doi.org\/10.1016\/j.drugalcdep.2011.07.011","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"5768_CR81","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1001\/jamapsychiatry.2015.3278","volume":"73","author":"ND Volkow","year":"2016","unstructured":"Volkow ND, Swanson JM, Evins AE, DeLisi LE, Meier MH, Gonzalez R, Bloomfield MA, Curran HV, Baler R (2016) Effects of cannabis use on human behavior, including cognition, motivation, and psychosis: a review. JAMA psychiatry 73(3):292\u2013297. https:\/\/doi.org\/10.1001\/jamapsychiatry.2015.3278","journal-title":"JAMA psychiatry"},{"issue":"2","key":"5768_CR82","doi-asserted-by":"publisher","first-page":"178","DOI":"10.2478\/aiht-2018-69-3096","volume":"69","author":"S Vu\u010dini\u0107","year":"2018","unstructured":"Vu\u010dini\u0107 S, Kilibarda V, \u0110or\u0111evi\u0107 S, \u0110or\u0111evi\u0107 D, Perkovi\u0107-Vuk\u010devi\u0107 N, Vukovi\u0107-Ercegovi\u0107 G, Antonijevi\u0107 B, \u0106ur\u010di\u0107 M, Antonijevi\u0107 E, Brajkovi\u0107 G (2018) Clinical and analytical experience of the National Poison Control Centre with synthetic cannabinoids. Archives of Industrial Hygiene and Toxicology 69(2):178\u2013185. https:\/\/doi.org\/10.2478\/aiht-2018-69-3096","journal-title":"Archives of Industrial Hygiene and Toxicology"},{"key":"5768_CR83","unstructured":"World Health Organization (2014) JWH-018 critical review report. World Health Organization. https:\/\/www.who.int\/medicines\/areas\/quality_safety\/4_5_review.pdf. Accessed 1 February 2019"},{"key":"5768_CR84","unstructured":"World Health Organization (2016) MDMB-CHMICA. Critical review report. World Health Organization. https:\/\/www.who.int\/medicines\/access\/controlled-substances\/4.9_MDMB-CHMICA_CritReview.pdf?ua=1. Accessed 4 March 2020"},{"issue":"1","key":"5768_CR85","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1080\/03602532.2018.1430824","volume":"50","author":"MT Zanda","year":"2018","unstructured":"Zanda MT, Fattore L (2018) Old and new synthetic cannabinoids: lessons from animal models. Drug Metab Rev 50(1):54\u201364. https:\/\/doi.org\/10.1080\/03602532.2018.1430824","journal-title":"Drug Metab Rev"},{"issue":"7","key":"5768_CR86","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1177\/0269881108089581","volume":"22","author":"L Zuurman","year":"2008","unstructured":"Zuurman L, Roy C, Schoemaker R, Hazekamp A, Den Hartigh J, Bender J, Verpoorte R, Pinquier J, Cohen A, Van Gerven J (2008) Effect of intrapulmonary tetrahydrocannabinol administration in humans. Journal of psychopharmacology 22(7):707\u2013716. https:\/\/doi.org\/10.1177\/0269881108089581","journal-title":"Journal of psychopharmacology"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-021-05768-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00213-021-05768-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-021-05768-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T01:03:55Z","timestamp":1652663035000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00213-021-05768-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,26]]},"references-count":86,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["5768"],"URL":"https:\/\/doi.org\/10.1007\/s00213-021-05768-0","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,26]]},"assertion":[{"value":"13 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}